Latest Views & News

Cancer Trial King is Worth a Look as It Keeps on Growing in a Growing Medical World

By Malcolm Stacey | Tuesday 16 August 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Hello Share Swappers. Medical companies have a favourable spot in my humble musings on possible share success. Today’s choice for your further perusal is Ergomed (ERGO). This is a niche company, another reason for me to favour it.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Quiz

The ShareProphets Sunday Pub Quiz #160

 

VCP

Gyrations at Victoria Carpets

 

MADE

GOTCHA: Made.com admits it is fucked

 

Bull

Stuff happens but we are not stuffed

 

Quiz

The ShareProphets Sunday Pub Quiz #159

 

OCDO

Challenges continue at Ocado

 

ICON

Iconic Labs – back from the dead?

 

PUR

Pure Gold – Pure Ramping!

Sunday »

Quiz

The ShareProphets Sunday Pub Quiz #158

 

ORCA

Buy Orcadian Energy